Literature DB >> 31844922

When is the best time to perform external physical vibration lithecbole (EPVL) after retrograde intrarenal surgery (RIRS): a multi-center study based on randomized controlled trials.

Yifan Zhang1, Changbao Xu2, Youzhi Wang1, Rongjiang Wang3, Wenqi Wu4, Jiakai Yan3, Xiaojian Gu5, Xuehua Chen5, Xiang Wang6, Zhangqun Ye6, Guohua Zeng4.   

Abstract

To determine the best time to perform EPVL treatment by evaluating the efficacy and safety of active stone extraction in treating residual fragments at different time points after RIRS. All participants had renal or upper ureteral stones preoperatively and still had residual stones after receiving RIRS. They were prospectively randomized into four groups: patients in group A received EPVL 3 days after RIRS; patients in group B received EPVL 7 days after RIRS; patients in group C received EPVL 14 days after RIRS; patients in group D did not receive EPVL after RIRS. Follow-up examinations were performed on all participants. The results, including stone size and location, stone-free rate (SFR) and complications, were compared among the groups. There were 176 patients in total. The SFR in groups A, B, C and D were 62.22%, 40.91%, 14.28% and 11.11%, respectively, 7 days after RIRS. At 14 days after RIRS, the SFR was 80%, 59.09%, 42.86% and 26.67% in groups A, B, C and D, respectively. At 28 days after RIRS, the SFR was 91.11%, 84.09%, 76.19% and 51.11% in groups A, B, C and D, respectively. Group A had the highest SFR from 7 to 28 days, and group C had a higher SFR at 28 days after RIRS than group D (P < 0.05). The side effects were less in groups A and B than in group D 28 days after RIRS (P < 0.05). We recommended that the best time to perform EPVL is 3 days after RIRS, because it could achieve a high SFR at any point in time and reduced complications.

Entities:  

Keywords:  Active stone extraction; External physical vibration lithecbole; Residual stone; Retrograde intrarenal surgery

Mesh:

Year:  2019        PMID: 31844922     DOI: 10.1007/s00240-019-01175-5

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  6 in total

1.  3D printing technology in percutaneous nephrolithotomy: babyhood but will be promising.

Authors:  Weizhou Wu; Zhijian Zhao; Shike Zhang; WenQi Wu
Journal:  World J Urol       Date:  2020-01-03       Impact factor: 4.226

2.  What is the exact definition of stone dust? An in vitro evaluation.

Authors:  Etienne Xavier Keller; Vincent De Coninck; Steeve Doizi; Michel Daudon; Olivier Traxer
Journal:  World J Urol       Date:  2020-04-08       Impact factor: 4.226

3.  Is physical therapy effective following extracorporeal shockwave lithotripsy and retrograde intrarenal surgery: a meta-analysis and systematic review.

Authors:  Linjie Peng; Junjun Wen; Wen Zhong; Guohua Zeng
Journal:  BMC Urol       Date:  2020-07-09       Impact factor: 2.264

4.  A single center study that evaluates the preclinical use of a newly developed software and moving bed system to facilitate the spontaneous excretion of residual fragments after primary stone treatment (RIRS or PCNL).

Authors:  Tao Yang; Rijin Song; Xianghu Meng; Hanping Wei; Xinying Jiang; Xiaoliang Yuan; Xiaowu Liu; Zhimin Jiao; Jun Liu; Honglei Shi
Journal:  World J Urol       Date:  2021-10-23       Impact factor: 4.226

5.  Fibrin gel-assisted stone extraction in retrograde intrarenal surgery.

Authors:  Yue Yu; Haibo Xi; Yujun Chen; Xuwen Li; Wei Liu; Jieping Hu; Jun Deng; Xiaoqiang Liu; Longhui Lin; Chen Li; Mengzhen Wang; Bin Fu; Gongxian Wang; Renrui Kuang; Xiaochen Zhou
Journal:  BJU Int       Date:  2021-12-14       Impact factor: 5.969

6.  Technique, Feasibility, Utility, Limitations, and Future Perspectives of a New Technique of Applying Direct In-Scope Suction to Improve Outcomes of Retrograde Intrarenal Surgery for Stones.

Authors:  Vineet Gauhar; Bhaskar Kumar Somani; Chin Tiong Heng; Vishesh Gauhar; Ben Hall Chew; Kemal Sarica; Jeremy Yuen-Chun Teoh; Daniele Castellani; Mohammed Saleem; Olivier Traxer
Journal:  J Clin Med       Date:  2022-09-27       Impact factor: 4.964

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.